PARKINSON'S DRUG REDUCES DISEASE MARKERS IN BREAKTHROUGH TRIAL

Summary from the TLDR newsletter

A novel therapy for Parkinson's disease has shown promise in early clinical trials. UB-312 is designed to clear toxic clumps of a protein thought to be responsible for the disease. It has been shown to be generally safe with relatively mild side effects. There are currently no treatments that address the underlying condition of Parkinson's. The therapy's initial success is exciting as it suggests that scientists are on the right path to finding a safe and effective means of improving quality of life for Parkinson's patients.